Sign up to save your podcasts
Or
Share Generic Competition for Dimethyl Fumarate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Generic Competition for Dimethyl Fumarate
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
View all episodes
By American Academy of Neurology
4.7
272272 ratings
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
More shows like Neurology® Podcast
View all
JAMA Editors' Summary
130 Listeners
NEJM This Week
325 Listeners
Practical Neurology Podcast
45 Listeners
JAMA Clinical Reviews
492 Listeners
The Curbsiders Internal Medicine Podcast
3,320 Listeners
JAMA Neurology Author Interviews
14 Listeners
Core IM | Internal Medicine Podcast
1,086 Listeners
Neurology Today in 5
21 Listeners
Annals On Call Podcast
185 Listeners
The Clinical Problem Solvers
515 Listeners
Neurology Minute
132 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
348 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
366 Listeners
Continuum Audio
77 Listeners